This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsOlink Holding（6XA）株式概要Olink Holding AB (publish)社は、学術機関、政府機関、バイオ製薬機関、バイオテクノロジー機関、サービスプロバイダー、その他ライフサイエンス研究に特化した機関向けに、バイオテクノロジー製品およびサービスの開発、製造、マーケティング、販売を行っている。 詳細6XA ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長4/6過去の実績0/6財務の健全性6/6配当金0/6報酬収益は年間152.39%増加すると予測されています リスク分析リスクチェックの結果、6XA 、リスクは検出されなかった。すべてのリスクチェックを見る6XA Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW479,582 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA479,582 investors already sharing narrativesYour Fair Value€Current Price€24.00123.3% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-36m401m2016201920222025202620282031Revenue US$401.5mEarnings US$50.8mAdvancedSet Fair ValueView all narrativesOlink Holding AB (publ) 競合他社GerresheimerSymbol: XTRA:GXIMarket cap: €924.3mEvotecSymbol: XTRA:EVTMarket cap: €615.4mSCHOTT Pharma KGaASymbol: XTRA:1SXPMarket cap: €3.1bSartoriusSymbol: XTRA:SRT3Market cap: €13.8b価格と性能株価の高値、安値、推移の概要Olink Holding過去の株価現在の株価US$24.0052週高値US$24.0052週安値US$13.10ベータ0.521ヶ月の変化4.35%3ヶ月変化12.15%1年変化42.01%3年間の変化-17.81%5年間の変化n/aIPOからの変化-6.80%最新ニュースお知らせ • Jul 11Olink Holding AB (publ)(NasdaqGM:OLK) dropped from NASDAQ Composite IndexOlink Holding AB (publ) has been dropped from NASDAQ Composite Index .Breakeven Date Change • Jul 11Forecast breakeven date moved forward to 2024The 4 analysts covering Olink Holding previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of US$11.3m in 2024. Earnings growth of 152% is required to achieve expected profit on schedule.お知らせ • Jun 08Olink® Target 48 Immune Surveillance Panel – the Next Frontier in Immune Biomarker Profiling with Absolute ConfidenceOlink Holding AB (publ) announced the introduction of Olink Target 48 Immune Surveillance, a validated multiplexed protein assay panel that offers a detailed view of the immune system for in-depth monitoring of inflammation and immune response in clinical research. Biomarker selection for Olink Target 48 Immune Surveillance were designed to give researchers the most effective platform for detecting and quantifying up to 44 well-established biomarkers across key immunological processes in as little as 1µL of sample. When combined with the Olink Target 48 Cytokine panel, scientists can simultaneously detect and quantify up to 89 immune-related proteins while still only using 2µL of sample. This represents a powerful new tool for identifying protein signatures across a range of important therapeutic areas including inflammation, immune response, immuno-oncology and infectious diseases. Developed using Olink’s proven PEA™ technology, Olink Target 48 Immune Surveillance delivers complete confidence with transparent quality control. In addition to internal quality control and validation, Olink works closely with the research community to further test, validate, and improve the performance of products.お知らせ • May 31Researchers Use Olink®? Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before DiagnosisOlink Holding AB (publ) reported the publication of a landmark study using the Olink Explore platform to identify proteins in the blood that may provide a 7-year warning for various cancers. The findings, published in Nature Communications, illustrate the tremendous potential of proteomics to revolutionize cancer detection, allowing for intervention at much earlier stages, potentially leading to better treatment outcomes and even prevention. Early Detection - A Game Changer. In the groundbreaking work, conducted by Oxford Population Health and funded by Cancer Research UK, researchers describe how they used Olink's next-generation proteomics platform to analyze blood samples from over 44,000 individuals. They were able to pinpoint 371 proteins linked to 19 different cancers, including 107 proteins that were detectable in individuals more than seven years before cancer diagnosis. Olink - Unlocking the Power of Proteomics. Olink's innovative proteomics solution played a pivotal role in the Oxford Population Health research. Owing to its scalability and specificity, researchers were able to accurately analyze a huge number of proteins across tens of thousands of samples, uncovering crucial information hidden within the human body's complex protein makeup. This study is a powerful example of how proteomics is driving a new era of discovery. Details of the study will be presented as part of the Olink Proteomics Corporate Symposium at European Society of Human Genetics conference in Berlin on June 1 - 4. Dr Atkins, alongside other speakers, will describe how the UK Biobank Pharma Proteomics Project, the world's largest proteomics study backed by 13 leading pharmaceutical companies, analyzed samples from over 54,000 participants and identified over 20,000 novel genetic associations with plasma protein levels, finally helping to bridge the gap between genetics and disease pathology. The Road ahead - Refining and Developing Solutions. While these findings hold immense promise for the future of cancer management, the research team emphasized the need for further investigation. Understanding the specific role these proteins play in cancer development and identifying the most reliable ones for testing are crucial next steps.Reported Earnings • May 13First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.11 loss in 1Q 2023)First quarter 2024 results: US$0.13 loss per share (further deteriorated from US$0.11 loss in 1Q 2023). Revenue: US$28.8m (up 4.7% from 1Q 2023). Net loss: US$16.1m (loss widened 15% from 1Q 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Breakeven Date Change • Mar 26Forecast breakeven date pushed back to 2025The 4 analysts covering Olink Holding previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of US$12.4m in 2025. Average annual earnings growth of 61% is required to achieve expected profit on schedule.最新情報をもっと見るRecent updatesお知らせ • Jul 11Olink Holding AB (publ)(NasdaqGM:OLK) dropped from NASDAQ Composite IndexOlink Holding AB (publ) has been dropped from NASDAQ Composite Index .Breakeven Date Change • Jul 11Forecast breakeven date moved forward to 2024The 4 analysts covering Olink Holding previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of US$11.3m in 2024. Earnings growth of 152% is required to achieve expected profit on schedule.お知らせ • Jun 08Olink® Target 48 Immune Surveillance Panel – the Next Frontier in Immune Biomarker Profiling with Absolute ConfidenceOlink Holding AB (publ) announced the introduction of Olink Target 48 Immune Surveillance, a validated multiplexed protein assay panel that offers a detailed view of the immune system for in-depth monitoring of inflammation and immune response in clinical research. Biomarker selection for Olink Target 48 Immune Surveillance were designed to give researchers the most effective platform for detecting and quantifying up to 44 well-established biomarkers across key immunological processes in as little as 1µL of sample. When combined with the Olink Target 48 Cytokine panel, scientists can simultaneously detect and quantify up to 89 immune-related proteins while still only using 2µL of sample. This represents a powerful new tool for identifying protein signatures across a range of important therapeutic areas including inflammation, immune response, immuno-oncology and infectious diseases. Developed using Olink’s proven PEA™ technology, Olink Target 48 Immune Surveillance delivers complete confidence with transparent quality control. In addition to internal quality control and validation, Olink works closely with the research community to further test, validate, and improve the performance of products.お知らせ • May 31Researchers Use Olink®? Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before DiagnosisOlink Holding AB (publ) reported the publication of a landmark study using the Olink Explore platform to identify proteins in the blood that may provide a 7-year warning for various cancers. The findings, published in Nature Communications, illustrate the tremendous potential of proteomics to revolutionize cancer detection, allowing for intervention at much earlier stages, potentially leading to better treatment outcomes and even prevention. Early Detection - A Game Changer. In the groundbreaking work, conducted by Oxford Population Health and funded by Cancer Research UK, researchers describe how they used Olink's next-generation proteomics platform to analyze blood samples from over 44,000 individuals. They were able to pinpoint 371 proteins linked to 19 different cancers, including 107 proteins that were detectable in individuals more than seven years before cancer diagnosis. Olink - Unlocking the Power of Proteomics. Olink's innovative proteomics solution played a pivotal role in the Oxford Population Health research. Owing to its scalability and specificity, researchers were able to accurately analyze a huge number of proteins across tens of thousands of samples, uncovering crucial information hidden within the human body's complex protein makeup. This study is a powerful example of how proteomics is driving a new era of discovery. Details of the study will be presented as part of the Olink Proteomics Corporate Symposium at European Society of Human Genetics conference in Berlin on June 1 - 4. Dr Atkins, alongside other speakers, will describe how the UK Biobank Pharma Proteomics Project, the world's largest proteomics study backed by 13 leading pharmaceutical companies, analyzed samples from over 54,000 participants and identified over 20,000 novel genetic associations with plasma protein levels, finally helping to bridge the gap between genetics and disease pathology. The Road ahead - Refining and Developing Solutions. While these findings hold immense promise for the future of cancer management, the research team emphasized the need for further investigation. Understanding the specific role these proteins play in cancer development and identifying the most reliable ones for testing are crucial next steps.Reported Earnings • May 13First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.11 loss in 1Q 2023)First quarter 2024 results: US$0.13 loss per share (further deteriorated from US$0.11 loss in 1Q 2023). Revenue: US$28.8m (up 4.7% from 1Q 2023). Net loss: US$16.1m (loss widened 15% from 1Q 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Breakeven Date Change • Mar 26Forecast breakeven date pushed back to 2025The 4 analysts covering Olink Holding previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of US$12.4m in 2025. Average annual earnings growth of 61% is required to achieve expected profit on schedule.Reported Earnings • Mar 26Full year 2023 earnings released: US$0.25 loss per share (vs US$0.11 loss in FY 2022)Full year 2023 results: US$0.25 loss per share (further deteriorated from US$0.11 loss in FY 2022). Revenue: US$169.6m (up 21% from FY 2022). Net loss: US$31.6m (loss widened 146% from FY 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.お知らせ • Mar 09Olink Holding AB (publ), Annual General Meeting, Apr 19, 2024Olink Holding AB (publ), Annual General Meeting, Apr 19, 2024.お知らせ • Jan 18Olink Holding AB Announces Promotion of Maria Liminga Björk to Chief Research and Development OfficerOn January 16, 2024, Olink Holding AB announced the promotion of Maria Liminga Björk (PhD) to Chief Research and Development Officer. Ms. Björk joined Olink as Vice President of Research and Development in March 2023. Prior to her role at Olink, Ms. Björk served as Director of BioProcess Research and Development at Cytiva, a Danaher Corporation subsidiary, from 2020 to 2023. In this role, Ms. Björk led an organization responsible for development of novel purification solutions for the biopharmaceutical industry. From 2016 to 2020, Ms. Björk directed the Resin and Ligand Department at GE HealthCare Technologies Inc. (d/b/a GE HealthCare). Ms. Björk holds a Masters in Pharmaceutical Biosciences and a PhD in Biochemical Pharmacology from Uppsala University.Reported Earnings • Nov 17Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0.011 loss in 3Q 2022)Third quarter 2023 results: US$0.01 loss per share. Revenue: US$44.2m (up 39% from 3Q 2022). Net loss: US$1.82m (loss widened 41% from 3Q 2022). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.お知らせ • Oct 26Olink Holding AB (publ) to Report Q3, 2023 Results on Nov 15, 2023Olink Holding AB (publ) announced that they will report Q3, 2023 results Pre-Market on Nov 15, 2023お知らせ • Oct 07Olink Holding AB (publ) Demonstrates the Power of the Olink Explore Platform for Driving Impactful Proteogenomic Studies At the Population ScaleOlink Holding AB (publ) reported the publication of three articles in the prestigious scientific journal, Nature, that demonstrate the power of the Olink Explore platform for driving impactful proteogenomic studies at the population scale. The studies each used data generated from the UK Biobank Pharma Proteomics Project (UKB-PPP), whereby 13 pharmaceutical companies generated new proteomic data from accessing the UK Biobank. Using the Olink Explore platform, researchers measured around 3,000 proteins in more than 54,000 UKB participant samples. By combining genomic and proteomic analyses at an unprecedented scale, a wealth of new information is available on the genetic effects on protein expression and phenotypic outcomes. The findings illustrate the immense value of proteogenomics in elucidating biological mechanisms, identifying actionable new biomarkers, and accelerating drug development efforts. The paper by Sun et al. from the UKB-PPP consortium provides the first detailed summary of the data, accompanied by downstream GWAS-based proteogenomic analyses, protein quantitative trait loci (pQTL) mapping, cross- section disease associations, and proteomic predictions of demographic factors and physiological functions. By uncovering over 14,000 genetic associations with protein expression levels, 81% of which are novel, their findings from this landmark paper clearly show the importance of high-throughput protein measurements for identifying important biological pathways and their impact on health. A second paper by Dhindsa et al., primarily authored by consortium members from AstraZeneca, used the dataset described in the paper to study genetic associations of rare protein-coding variants with protein expression. The results shed light on the vital role of rare variants in plasma protein level variation and biological outcomes, further underscoring the crucial need for large-scale proteogenomic studies to enable such discoveries. The third article by Eldjarn et al. describes a study where the Olink-generated results in the UKB-PPP dataset were compared to the proteogenomic analysis of a large Icelandic population cohort using an aptamer-based technology. While both platforms identified a large number of genetic associations with protein levels, a significantly higher proportion of the proteins measured using Olink (72% versus 43% when using the aptamer-based technology) had cis-pQTLs associated with them, providing strong genetic corroboration for superior specificity of the Olink assays. Furthermore, median CV ratios were lower for the Olink assays, indicating they were more precise on average.お知らせ • Sep 19Olink Holding AB (Publ) Announces the Introduction of Olink(R) Target 48 Mouse Cytokine PanelOlink Holding AB (publ) announced the introduction of Olink(R) Target 48 Mouse Cytokine Panel, a validated multiplexed protein panel that offers a detailed view of the murine immune system, enabling in-depth disease modelling, longitudinal studies and translational research. The Olink Target 48 Mouse Cytokine Panel represents a new standard in immunoassays giving researchers the ability to accurately measure 43 carefully selected immune-related proteins using as little as 1ul of sample volume. Offering multiplexing with unparalleled specificity combined with high sensitivity, the T48 Mouse Cytokine panel unlocks true longitudinal studies over multiple timepoints in individual mice. The transparent validation and streamlined workflow maintains the exceptional standards of performance that users have come to expect from Olink. The addition of a targeted mouse panel with absolute quantification capabilities adds to Olink`s broad portfolio of proteomics solutions. From pre-clinical mouse models to human clinical applications, Olink provides solutions encompassing all stages of drug development and disease modelling. The Olink Target 48 Mouse Cytokine Panel was designed to deliver an in-depth view of cytokine signalling and inflammatory pathways for pre-clinical and translational research. It can be utilized across key application areas to deepen current understanding of molecular pathways involved in the disease initiation and progression. Olink Target 48 Mouse Cytokine Panel is fully compatible with the Olink(R) Signature Q100, a high performance, auto-calibrated instrument for data readout that facilitates unattended operation. Work efficiency is further increased by the streamlined assay workflow with minimal hands-on time.Breakeven Date Change • Aug 11Forecast breakeven date moved forward to 2024The 5 analysts covering Olink Holding previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of US$15.8m in 2024. Average annual earnings growth of 60% is required to achieve expected profit on schedule.お知らせ • Aug 10Olink Holding AB (Publ) Reiterates Revenue Guidance for the Full Year 2023Olink Holding AB (publ) reiterated revenue guidance for the full year 2023. For the year, company expects revenue guidance of $192 million to $200 million.Reported Earnings • Aug 10Second quarter 2023 earnings released: US$0.067 loss per share (vs US$0.04 loss in 2Q 2022)Second quarter 2023 results: US$0.067 loss per share (further deteriorated from US$0.04 loss in 2Q 2022). Revenue: US$29.4m (up 7.0% from 2Q 2022). Net loss: US$8.27m (loss widened 72% from 2Q 2022). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.お知らせ • Jul 14Olink Holding AB (publ) to Report Q2, 2023 Results on Aug 09, 2023Olink Holding AB (publ) announced that they will report Q2, 2023 results Pre-Market on Aug 09, 2023お知らせ • Jul 13Olink Holding AB (Publ) Announces the Introduction of Olink(R) Explore HtOlink Holding AB (publ) announced the introduction of Olink(R) Explore HT, a transformational solution for high-throughput proteomics delivering unmatched specificity, scalability, and workflow simplicity. Olink Explore HT represents a significant advancement in next generation proteomics, allowing scientists to accurately measure over 5,300 proteins using only 2ul of sample with a completely reimagined and streamlined workflow, including a highly automated data analysis platform. In addition to delivering over 80% more unique protein assays than the previous generation product, Olink Explore HT increases sample throughput by 4X and data output by 7X with a >30% reduction in cost per data point and >20% reduction in workflow processing cost. Importantly, these innovations substantially reduce the environmental footprint with a 6-fold decrease in components and 10-fold reduction in boxes. Olink Explore HT was designed to unlock the immense value of proteomics at any scale and advance multi-omic research. It can be utilized across a wide range of therapeutic areas to deepen current understanding of molecular pathways involved in the development, progression, and outcome of disease. Olink Explore HT will also empower new discoveries in drug development, from target discovery based on identification of proteins causal in disease, to actionable insights into mode of action studies and repurposing of therapeutics from reinterrogation of existing samples from clinical trials.Buying Opportunity • May 14Now 21% undervaluedOver the last 90 days, the stock is up 1.0%. The fair value is estimated to be €25.47, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 39% over the last year. Earnings per share has grown by 64%. Revenue is forecast to grow by 48% in a year. Earnings is forecast to grow by 35% in the next year.Reported Earnings • May 12First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.10 loss in 1Q 2022)First quarter 2023 results: US$0.11 loss per share (further deteriorated from US$0.10 loss in 1Q 2022). Revenue: US$27.5m (up 21% from 1Q 2022). Net loss: US$14.0m (loss widened 15% from 1Q 2022). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.お知らせ • May 12Olink Holding AB (Publ) Provides Earnings Guidance for the Year 2023Olink Holding AB (publ) provided earnings guidance for the year 2023. For the year, the company expects full year reported revenue to be in the range of $192 million to $200 million, representing growth of approximately 37% to 43% on a reported basis, and growth of approximately 38% to 44% on a constant currency basis.Buying Opportunity • Mar 28Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be €26.15, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 38% over the last 3 years. Earnings per share has grown by 116%. Revenue is forecast to grow by 41% in a year. Earnings is forecast to decline by 26% in the next year.Breakeven Date Change • Feb 22Forecast to breakeven in 2024The 6 analysts covering Olink Holding expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$8.56m in 2024. Average annual earnings growth of 84% is required to achieve expected profit on schedule.Reported Earnings • Feb 22Full year 2022 earnings released: US$0.11 loss per share (vs US$0.43 loss in FY 2021)Full year 2022 results: US$0.11 loss per share (improved from US$0.43 loss in FY 2021). Revenue: US$139.8m (up 47% from FY 2021). Net loss: US$12.9m (loss narrowed 70% from FY 2021). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.Buying Opportunity • Jan 21Now 20% undervaluedOver the last 90 days, the stock is up 12%. The fair value is estimated to be €22.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 38% over the last 3 years. Earnings per share has grown by 116%. Revenue is forecast to grow by 45% in a year. Earnings is forecast to grow by 32% in the next year.お知らせ • Jan 10+ 1 more updateOlink Holding AB (publ) to Report Fiscal Year 2022 Results on Feb 21, 2023Olink Holding AB (publ) announced that they will report fiscal year 2022 results Pre-Market on Feb 21, 2023Buying Opportunity • Jan 05Now 22% undervaluedOver the last 90 days, the stock is up 49%. The fair value is estimated to be €26.20, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 38% over the last 3 years. Earnings per share has grown by 116%. Revenue is forecast to grow by 46% in a year. Earnings is forecast to grow by 43% in the next year.Reported Earnings • Nov 16Third quarter 2022 earnings released: US$0.011 loss per share (vs US$0.046 loss in 3Q 2021)Third quarter 2022 results: US$0.011 loss per share (improved from US$0.046 loss in 3Q 2021). Revenue: US$31.8m (up 59% from 3Q 2021). Net loss: US$1.29m (loss narrowed 77% from 3Q 2021). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.Board Change • Nov 16High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 2 experienced directors. No highly experienced directors. Director Tommi Unkuri is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Nov 15Olink® Flex, A New, Unique and Fully Flexible Low-Plex Proteomics Solution Using Absolute QuantificationOlink Holding AB (publ) announced that it is now taking orders for Olink® Flex, a fully flexible made-to-order product to select and combine up to 21 human proteins using absolute quantification in one biomarker panel. With the introduction of Olink® Flex, the Company offers a mix-and-match solution for efficient creation of custom protein biomarker panels with uncompromised data quality, unparalleled specificity, high sensitivity, broad dynamic range, and short turnaround time. Additionally, the solution features absolute quantification methodology for protein concentration measurement, an important feature for many applications spanning clinical to basic research. Using an online panel builder in Olink® Insight, customers can freely pick and choose 15 to 21 pre-validated assays from over 200 human protein biomarkers covering major biological pathways such as inflammation, immuno-oncology and oncology, neurology, and cardiovascular disease. With this new product line, Olink enables customers to easily design customized biomarker panels that include the protein assays of their choice, tailored to specific research needs. This latest high-performance solution based on Olink® Proximity Extension Assay (PEA) technology accelerates targeted protein biomarker studies in academic and clinical research to investigate inflammatory processes and immune responses, understand mechanisms of disease and validate unique biomarker signatures. Olink Flex is fully compatible with Olink® Signature Q100, a low maintenance, auto-calibrated instrument for data readout that facilitates unattended operation. Work efficiency is further increased by the streamlined assay workflow with minimal hands-on time and no need for time-consuming washing steps. With this latest addition, the Olink technology platform now scales from the high-plex product Olink® Explore 3072, to mid-plex Olink® Target 96 and Target 48, down to customized low-plex Olink® Focus and Olink® Flex.Reported Earnings • Nov 11Third quarter 2022 earnings released: US$0.01 loss per share (vs US$0.046 loss in 3Q 2021)Third quarter 2022 results: US$0.01 loss per share (improved from US$0.046 loss in 3Q 2021). Revenue: US$31.8m (up 59% from 3Q 2021). Net loss: US$1.29m (loss narrowed 77% from 3Q 2021). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.お知らせ • Nov 11+ 1 more updateOlink Holding AB (publ) Provides Earnings Guidance for the Full Year 2022Olink Holding AB (publ) provides earnings guidance for the full year 2022. For the period, the company expects revenue to be in the range of $138 million and $142 million.お知らせ • Oct 25Olink Holding AB (Publ) Announces the Launch of Olink(R) InsightOlink Holding AB (publ) announced the launch of Olink(R) Insight, providing customers with an open-access online platform to share knowledge, with multiple tools to simplify users' data experiences, and to provide more timely insights from their protein studies. Olink(R) Insight has been created from the ground up to address the complex challenges of proteomic data analysis, introducing a modern and user-friendly new interface to explore Olink(R) NPX(TM) data, which will help to deliver on the urgent scientific questions asked by the community. With this new digital platform, Olink makes a long-term commitment to develop and implement features for customers that simplify the data management experience and leverage its considerable value. The user data journey is improved with tools that help translate biological pathways to generate a list of candidate protein biomarkers, enabling improved experiment planning and setup, post-run data analysis; and with analytical tools, applications, scripts, and shared expertise, to provide users a faster time to value with their data. Olink(R) Insight Product details and functionalities An open-access online portal that supports users in understanding and interpreting their proteomics data, by visualizing initial findings and thereby achieving insights faster. Its significant features include: PathwaE Explorer - Graphically represents the proteome and coverage of Olink panels in biological pathways. Explplores which proteins are involved in a specific pathway to help with interpretation of data and generation of actionable results. Reveals and helps users understand connections between proteins and human biology. Built on Reactome, an open-source peer reviewed database. Annotation - Draw biological conclusions from proteomic data by listing biomarker-specific information about tissue specificity, how the corresponding gene functions at the molecular level, where in the cell it functions, what biological processes it helps to carry out, and variability in a normal cohort. Normal Ranges - Explore the natural variability of proteins before selecting biomarkers for a study; or after analysis, compare outcomes to observed variability in samples to that of a "normal" cohort. A reference database based on protein profiling of healthy individuals. Disease Atlas (by year end) - Compare and explore observed protein expression profiles in the most common diseases, generated by protein profiling of patients. The first version of the Disease Atlas will focus on cancer, and will later expand to include other common diseases, such as cardiovascular, neurological, infectious, and autoimmune diseases; as well as other conditions. Publication Explorer - Get fast insights into proteins of interest, such as a list of significant hits from a study; based on cutting-edge abstract mining technology. Find key abstracts where significant hits co-occur with each other, with key words, and diseases. Data Stories - Showcase Olink 'best practice analytics' on a real and relevant publicly available data set demonstrating how results can be analyzed and visualized in practice.お知らせ • Oct 14Olink Holding AB (publ) to Report Q3, 2022 Results on Nov 10, 2022Olink Holding AB (publ) announced that they will report Q3, 2022 results Pre-Market on Nov 10, 2022お知らせ • Sep 01Olink Holding AB (Publ) Announces Management AppointmentsOlink Holding AB (publ) announced several appointments in its leadership structure. Olink Chief Commercial Officer (CCO) Carl Raimond will be appointed President, effective upon the hiring of a new CCO, which is expected by the end of the year. In the interim, Carl will continue his strong stewardship of the commercial organization during Olink’s second half of 2022 and lead the transition of CCO duties. In this newly created position, Carl’s role will expand from leadership of the commercial group to responsibility for corporate functions, while continuing to report to CEO Jon Heimer. In addition, Anna Marsell will become Chief Operating Officer (COO) effective December 1st, 2022. Anna has a strong track record in transforming and scaling growth-driven international organizations and will join Olink from Galderma where she has held several leadership positions with increasing responsibility over the past ten years, including General Manager/Head of Nordic, and senior roles in decision support and strategic planning. Olink’s current COO, Fredrik Netzel, will be appointed VP Operations, his role to include management of Olink’s supply chain, a function of critical importance to Olink’s success and differentiation. Carl Raimond has served as Olink’s CCO since October 2020, previously serving as the Company’s Senior Vice President of Sales beginning in August 2020. Prior to Olink, he served in various executive commercial leadership roles at PerkinElmer Inc. including Vice President and General Manager of Americas Sales and Service, as well as Global Vice President and General Manager of Sales and Service for the Discovery and Analytical Solutions Division. Before this, he served as the Vice President and General Manager of the Americas Life Science Sales & Field Operations of Agilent Technologies Inc. Carl received his Bachelor of Arts in zoology from State University of New York College at Oswego, and his Master of Science in biology from State University of New York College at Brockport. Anna Marsell brings more than 15 years of international experience from the pharma and medtech industry with various roles in R&D, project management, sales and marketing, as well as company governance and general management. Her most recent role is General Manager for the Nordic region of Galderma, delivering sustainable organic growth and increased market share. During her 10 years at Galderma she has held various senior leadership roles in global strategic marketing, product development, commercial operations, Uppsala Site management, as well as in strategic corporate governance when based in Galderma HQ in Lausanne, Switzerland. Prior to joining Galderma, Anna spent 7 years in various R&D and product marketing roles within medtech, focused on cardiovascular technology at Radi Medical Systems and St. Jude Medical in the U.S. and Sweden. Anna is an inspirational leader with a strong track record in delivering outstanding commercial results, driving innovation and in managing high-performing teams. She holds a Master’s in Molecular Biotechnology from Uppsala University and an Associate’s Certificate in Project Management from The George Washington University and ESI International.Reported Earnings • Aug 12Second quarter 2022 earnings released: US$0.04 loss per share (vs US$0.089 loss in 2Q 2021)Second quarter 2022 results: US$0.04 loss per share (up from US$0.089 loss in 2Q 2021). Revenue: US$27.5m (up 56% from 2Q 2021). Net loss: US$4.82m (loss narrowed 55% from 2Q 2021). Over the next year, revenue is forecast to grow 52%, compared to a 13% growth forecast for the industry in Germany.お知らせ • Aug 12Olink Holding AB (Publ) Provides Revenue Guidance for the Fiscal Year 2022Olink Holding AB (publ) provided revenue guidance for the fiscal year 2022. for the year, the company expects revenue in range of $138 million to $145 million and continues to expect revenue will be weighted toward the second half of the year and fourth quarter specifically.お知らせ • Jul 15Olink Holding AB (publ) to Report Q2, 2022 Results on Aug 11, 2022Olink Holding AB (publ) announced that they will report Q2, 2022 results Pre-Market on Aug 11, 2022お知らせ • Jun 29Release of Olink Analyze 3.1 Streamlines Proteomic Analysis to Connect Data to Biological InsightOlink Holding AB (publ) announced the release of Olink® Analyze 3.1. Olink® Analyze is an R software package, a collection of functions written in R programming language, created to streamline the analysis of Olink data. R is a free and open-source programming language that is widely used for statistics and data science. Olink® Analyze enables users to easily extract biological insight from Olink data using built-in statistical analysis and visualization functions and expedites the data analysis process with quality control visualizations and easy integration with other R packages. Regardless of what Olink product is being used, Olink® Analyze 3.1 can help expedite the analysis pipeline. For the Olink® Target 48 product for analysis of immune response proteins, non-parametric functions have been added to easily analyze data in absolute quantification. For hypothesis generating studies, like those run with Olink® Explore 3072 for simultaneous analysis of up to 3,000 proteins, the heatmap function makes it even easier to detect global trends in Olink data. Pathway enrichment functions enable a seamless connection between statistical results and biological meaning. Olink® Analyze functions also help with data pre-processing, quality control and exploratory data analysis, statistical analysis, and data visualization. Olink® Analyze is easily accessible and can be installed from the Comprehensive R Archive Network (CRAN), R’s central software repository, and has undergone manual and automated review by CRAN maintainers. Whether trying to get a sense of data, developing new hypotheses, or looking for biomarkers of interest, Olink® Analyze can streamline the analysis process to get from data to insight faster.Reported Earnings • May 13First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.48 loss in 1Q 2021)First quarter 2022 results: US$0.10 loss per share (up from US$0.48 loss in 1Q 2021). Revenue: US$22.7m (up 66% from 1Q 2021). Net loss: US$12.2m (loss narrowed 34% from 1Q 2021). Over the next year, revenue is forecast to grow 51%, compared to a 13% growth forecast for the industry in Germany.お知らせ • May 13Olink Holding AB (publ) Provides Revenue Guidance for the Year 2022Olink Holding AB (publ) provided revenue guidance for the year 2022. Revenue guidance range of $138 million to $145 million and continues to expect revenue will be weighted toward the second half of the year and fourth quarter specifically.Breakeven Date Change • May 08Forecast breakeven date moved forward to 2023The 3 analysts covering Olink Holding previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 47% to 2022. The company is expected to make a profit of US$2.50m in 2023. Average annual earnings growth of 98% is required to achieve expected profit on schedule.Board Change • Apr 27High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 2 experienced directors. No highly experienced directors. Director Tommi Unkuri is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Apr 22Olink Holding AB (publ) to Report Q1, 2022 Results on May 12, 2022Olink Holding AB (publ) announced that they will report Q1, 2022 results Pre-Market on May 12, 2022Breakeven Date Change • Apr 13Forecast to breakeven in 2024The 4 analysts covering Olink Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 68% per year to 2023. The company is expected to make a profit of US$21.7m in 2024. Average annual earnings growth of 91% is required to achieve expected profit on schedule.お知らせ • Apr 08Olink Holding AB (publ) Announces Board AppointmentsOlink Holding AB (publ) at its AGM held on April 7, 2022, approved the appointment of Robert Schueren and Mary Reumuth as new Board Members.お知らせ • Feb 15Olink Holding AB (publ) Provides Revenue Guidance for 2022Olink Holding AB (publ) provided revenue guidance for 2022. The company expects full year 2022 revenue will be in the range of $138 million to $145 million, progressing along a seasonal pattern similar to 2021.Reported Earnings • Feb 15Full year 2021 earnings: Revenues exceed analyst expectationsFull year 2021 results: Revenue: US$95.0m (up 76% from FY 2020). Net loss: US$38.3m (loss widened 79% from FY 2020). Revenue exceeded analyst estimates by 2.5%. Over the next year, revenue is forecast to grow 50%, compared to a 27% growth forecast for the pharmaceuticals industry in Germany.お知らせ • Jan 12Olink Holding AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2022Olink Holding AB (publ) provided earnings guidance for the fourth quarter and full year 2022. For the quarter, the company's Revenues is expected to be between $43.2 million and $43.7 million, versus $27.2 million in the corresponding quarter of last year.For the year, the company's Revenues is expected to be between $94.5 million and $95.0 million, an increase of approximately 75% compared to the year ended December 31, 2020.Board Change • Dec 31High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Director Tommi Unkuri is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Dec 02Olink Holding AB (Publ) Announces Delivery of Olink® Explore 3072 Is Now StartingOlink Holding AB (publ) announced that the delivery of Olink® Explore 3072 is now starting, providing customers with access to its expanded library of approximately 3,000 carefully curated and validated assays that together cover of all major biological pathways. With the introduction of Olink® Explore 3072, the company offers customers the possibility to run either 96 or 384 samples per run. This means that the throughput will increase significantly, and customers can process over 4,600 samples per week per system, with almost 3,000 proteins measured for each sample. Moving from Olink® Explore 1536 to Olink® Explore 3072 increases the overall dynamic range covered by the Olink library. This will enable measurement of proteins present in higher concentration in the sample than was possible in earlier versions of the platform, such as the PSA protein, which is a key biomarker for prostate cancer diagnosis. Olink® Explore 3072 significantly increases the sample and assay throughput, and in addition expands the company's protein biomarker discovery offering, featuring its proprietary Proximity Extension Assay (PEA) high-multiplex immunoassay technology combined with next-generation sequencing (NGS) readout on the Illumina® NovaSeq and Illumina® NextSeq platforms. With this expansion, Olink will 1) double the number of available protein biomarkers, covering all major biological pathways, 2) increase the throughput, and 3) increase the dynamic range, especially for higher abundant proteins, while maintaining unparalleled sensitivity, specificity, and precision.お知らせ • Nov 24Olink Holding AB (publ) Announces Delivery of Olink® Signature Q100Olink Holding AB (publ) announced that it is now starting the delivery of Olink® Signature Q100, facilitating hands-on access for researchers to Olink technology with a new benchtop system dedicated to multiplex protein biomarker measurement. Olink® Signature Q100 now offers a new solution designed for readout of Olink® Target and Olink® Focus protein biomarker panels, enabling researchers to run Olink kits more easily and conveniently in their own labs using as little as one microliter of plasma or serum to measure protein concentrations for up to 92 proteins simultaneously. This new instrument will allow more researchers to access high-quality proteomics data with Olink technology. Key features: Developed specifically for the high quality of Olink® Target 96/48 and Focus (custom designed) protein biomarker panels, as well as future custom biomarker solutions presently under development – currently covering over 1100 different thoroughly validated protein assays. Low investment threshold, broadening access to protein biomarker analysis to more researchers than ever before. User-focused design and intuitive interface, including integrated software and IFC loader. Small, compact footprint.Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.046 loss per shareThe company reported a soft third quarter result with weaker control over costs, although losses were stable and revenues were flat. Third quarter 2021 results: Revenue: US$20.0m (flat on 3Q 2020). Net loss: US$5.47m (flat on 3Q 2020).お知らせ • Aug 12Olink Holding AB (Publ) Provides Earnings Guidance for the Year 2021Olink Holding AB (publ) provided earnings guidance for the year 2021. The company expects revenue to be in the range of $90 million to $92 million.お知らせ • Jul 23Olink Holding AB (publ) Announces UK Biobank Pharma Proteomics Project's Expansion of Ongoing Proteomics Study Of 53,000 Participants to the New Olink Explore 3072 PlatformOlink Holding AB (publ) announced that the UK Biobank Pharma Proteomics Project (UKB-PPP Consortium) has decided to expand the ongoing proteomics study of 53,000 participants to the new Olink® Explore 3072 platform, providing access to Olink´s expanded library of approximately 3,000 carefully curated and validated assays. The UK Biobank Pharma Proteomics Project (UKB-PPP), a partnership between UK Biobank and biopharmaceutical companies, is currently performing a large scientific studies of blood protein biomarkers conducted to date of 53,000 UK Biobank participants. The study aims to enable better understanding of disease biology and support innovative drug development for more effective therapies. Initially funded by ten biopharmaceutical companies, the consortium has now grown to twelve companies, further emphasizing the value of this important work. By expanding the study from Olink Explore 1536 to the new Olink Explore 3072 platform, utilizing Next Generation Sequencing (NGS) as a read-out to measure plasma protein concentration, UKB-PPP will double the number of available assays from almost 1,500 to close to 3,000. UK Biobank is a large-scale, biomedical database and research resource containing in-depth genetic and health information from half a million UK participants. The database, which is regularly augmented with additional data, is globally accessible to approved researchers and scientists undertaking vital research into the most common and life-threatening diseases. The project includes analysis of 56,000 samples from 53,000 participants and is funded by the twelve participating companies in UKB-PPP.お知らせ • Jul 16Olink Holding AB (publ) has completed a Follow-on Equity Offering in the amount of $232.5 million.Olink Holding AB (publ) has completed a Follow-on Equity Offering in the amount of $232.5 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Securities Offered: 7,500,000 Price\Range: $31お知らせ • Jul 14Olink Holding AB (publ) Provides Preliminary Unaudited Earnings Guidance for the Second Quarter Ended June 30, 2021Olink Holding AB (publ) provided preliminary unaudited earnings guidance for the second quarter ended June 30, 2021. For the period, the company expects revenue to be between $17.3 million and $17.7 million, compared to $7.9 million for the corresponding quarter of last year. Net loss to be between $10.4 million and $10.8 million, compared to $2.0 million for the corresponding quarter of last year.お知らせ • Jun 24Olink Announces the New Explore 3072 High Throughput Proteomics PlatformOlink Holding AB announced that it is taking orders for Olink Explore 3072, providing customers with access to its expanded library of 3,000 carefully curated and validated assays. Olink® Explore 3072 significantly expands the company's Explore protein biomarker discovery offering, featuring its proprietary Proximity Extension Assay (PEA) high-multiplex immunoassay technology combined with next-generation sequencing (NGS) readout on the Illumina® NovaSeq and Illumina® NextSeq platforms. With this expansion, Olink will double the number of available protein biomarker targets, covering all major biological pathways, and increasing the dynamic range while maintaining unparalleled sensitivity, specificity and precision. By using Olink Explore 3072, customers can experience a throughput of just over 4,600 samples per week per system, with almost 3000 proteins measured for each sample. The company will begin taking orders for kits and studies based on the expanded library beginning June 23, 2021, with deliveries expected to begin in the fourth quarter, 2021. Product details: Olink Explore 3072 enables rapid measurement of almost 3,000 human proteins in only 6 µL of plasma or serum. These carefully selected proteins provide broad coverage of the low abundant plasma proteome as well as broadening the dynamic range of the library to include more high-abundant proteins, and represent the latest step in the development of Olink's planned NGS-based library. The power of the NGS platform combined with an automation-enabled assay workflow enables unprecedented levels of throughput, with up to 14 million protein measurements/ week/ system. Each thoroughly validated assay maintains the exceptional standards of specificity, sensitivity, precision and dynamic range that Olink users have come to expect.お知らせ • Jun 16SCALLOP Launches Clinical Trial Arm to Uncover Next Level of Drug Target Insights from Proteomic ProfilingOlink Holding AB (publ) announced that the SCALLOP consortium (Systematic and Combined AnaLysis of Olink Proteins), a collaborative framework for discovery and follow-up of genetic associations with proteins on the Olink Proteomics platform, is launching a new clinical trial arm to bring together actors working on proteomic profiling in clinical trials. The new initiative is designed to enhance insights from clinical trial proteomic profiling, boost statistical power and uncover the next level of drug target insights. The participants will have access to a dedicated project coordinator and a GDPR compliant secure server that can be remotely accessed. The SCALLOP clinical trial arm initiative offers a uniform price of Olink protein profiling.お知らせ • May 21Olink Holding AB (Publ) Provides Earnings Guidance for the Year 2021Olink Holding AB (publ) provided earnings guidance for the year 2021. The company expected full year 2021 revenue to be in the range of $90 million to $92 million.お知らせ • May 05Olink Announces First Core Lab Running the Olink Explore Platform in Europe, Making It Available for More ResearchersOlink Holding AB (publ) announced that its Olink® Explore 1536/384 platform is now available to researchers in Europe through the SciLifeLab National Genomics Infrastructure and the Affinity Proteomics Uppsala unit at SciLifeLab Clinical and Immunological platform by their combined capability SciLifeLab Explore lab. This is the first core lab in Europe certified to offer the Olink Explore platform, comprising four protein biomarker panels for cardiovascular and metabolic diseases, oncology, neurology and inflammation. The platform enables researchers to define protein signatures that provide meaningful insights into human biology and dynamic changes in health and disease. Through the launch of Olink® Explore 1536 as kits earlier this year, laboratories are now able to set up the Olink Explore platform, providing additional analysis capacity to researchers. By combining Olink’s patented proximity extension assay technology with a high-throughput next generation sequencing readout on Illumina® NovaSeq and NextSeq instruments, close to 1,500 protein biomarker targets can be measured simultaneously in only a few microliters of biological sample, providing clinically relevant, actionable insights. This year, Olink plans to increase the library to approximately 3,000 protein biomarker targets. The PEA technology is based on two matching antibodies binding to the target protein. When the complementary DNA tags from the two antibodies come into close proximity, the tags hybridize and are extended making a unique DNA barcode for each analyzed protein. After amplification, digital DNA counting is performed using NGS and the resulting counts represent the concentration of the protein in the sample. This project has been made possible by grants from SciLifeLab and the Swedish Research Council’s Access to Infrastructure and by building a new joint-capability lab between NGI and APU at the Biomedical Centre in Uppsala.株主還元6XADE Life SciencesDE 市場7D0.8%-8.4%0.1%1Y42.0%0.1%-0.5%株主還元を見る業界別リターン: 6XA過去 1 年間で0.1 % の収益を上げたGerman Life Sciences業界を上回りました。リターン対市場: 6XA過去 1 年間で-0.5 % の収益を上げたGerman市場を上回りました。価格変動Is 6XA's price volatile compared to industry and market?6XA volatility6XA Average Weekly Movement2.2%Life Sciences Industry Average Movement6.4%Market Average Movement5.3%10% most volatile stocks in DE Market12.7%10% least volatile stocks in DE Market2.7%安定した株価: 6XA 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 6XAの 週次ボラティリティ は、過去 1 年間で9%から2%に減少しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト2004707Jon Heimerwww.olink.comOlink Holding AB (publish)は、学術機関、政府機関、バイオ製薬会社、バイオテクノロジー会社、サービスプロバイダー、その他ライフサイエンス研究機関向けに、バイオテクノロジー製品およびサービスの開発、製造、マーケティング、販売を行っている。同社の製品には、心血管・代謝疾患、腫瘍学、神経学、炎症性疾患向けのExplore 372およびExplore 384からなるOlink Explore、Olink Target製品ライン、低プレックスのアプリケーションおよびユースケースであるOlink Flex、および関心のあるさまざまなタンパク質や注目すべきタンパク質シグネチャーを特定した顧客向けのカスタム開発ソリューションからなるOlink Focus製品ラインがある。また、同社の製品には、qPCR読み出しプラットフォームであるOlink Signature Q100、試験デザインとコンサルテーション、サンプル調製とアッセイ実施、データ処理とQCからなるOlink Analysisサービス、データ解析とバイオインフォマティクスサービスがある。さらに、Olink正規化タンパク質発現（NPX）データ処理ソフトウェア（データのインポート、可視化を含むデータ解析、統計モデリングを可能にする専用ソフトウェア）、Olink Insight（プロテオミクスを加速するOlinkコミュニティのためのクラウドプラットフォーム）を提供している。同社は、スウェーデン、米国、その他のアメリカ大陸、その他のヨーロッパ、中東、アフリカ、日本、および国際的な直販部隊を通じて製品とサービスを販売している。以前はKnilo HoldCo ABとして知られていたが、2021年1月にOlink Holding AB (publ)に社名変更した。Olink Holding AB（publ）は2004年に設立され、スウェーデンのウプサラに本社を置いている。もっと見るOlink Holding AB (publ) 基礎のまとめOlink Holding の収益と売上を時価総額と比較するとどうか。6XA 基礎統計学時価総額€3.00b収益（TTM）-€31.07m売上高(TTM)€157.54m19.0xP/Sレシオ-96.5xPER（株価収益率6XA は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計6XA 損益計算書（TTM）収益US$170.89m売上原価US$56.60m売上総利益US$114.29mその他の費用US$148.00m収益-US$33.70m直近の収益報告Mar 31, 2024次回決算日該当なし一株当たり利益（EPS）-0.27グロス・マージン66.88%純利益率-19.72%有利子負債／自己資本比率0%6XA の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/07/11 19:35終値2024/07/11 00:00収益2024/03/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Olink Holding AB (publ) 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Mark MassaroBTIGKyle MiksonCanaccord GenuityMatthew SykesGoldman Sachs2 その他のアナリストを表示
お知らせ • Jul 11Olink Holding AB (publ)(NasdaqGM:OLK) dropped from NASDAQ Composite IndexOlink Holding AB (publ) has been dropped from NASDAQ Composite Index .
Breakeven Date Change • Jul 11Forecast breakeven date moved forward to 2024The 4 analysts covering Olink Holding previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of US$11.3m in 2024. Earnings growth of 152% is required to achieve expected profit on schedule.
お知らせ • Jun 08Olink® Target 48 Immune Surveillance Panel – the Next Frontier in Immune Biomarker Profiling with Absolute ConfidenceOlink Holding AB (publ) announced the introduction of Olink Target 48 Immune Surveillance, a validated multiplexed protein assay panel that offers a detailed view of the immune system for in-depth monitoring of inflammation and immune response in clinical research. Biomarker selection for Olink Target 48 Immune Surveillance were designed to give researchers the most effective platform for detecting and quantifying up to 44 well-established biomarkers across key immunological processes in as little as 1µL of sample. When combined with the Olink Target 48 Cytokine panel, scientists can simultaneously detect and quantify up to 89 immune-related proteins while still only using 2µL of sample. This represents a powerful new tool for identifying protein signatures across a range of important therapeutic areas including inflammation, immune response, immuno-oncology and infectious diseases. Developed using Olink’s proven PEA™ technology, Olink Target 48 Immune Surveillance delivers complete confidence with transparent quality control. In addition to internal quality control and validation, Olink works closely with the research community to further test, validate, and improve the performance of products.
お知らせ • May 31Researchers Use Olink®? Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before DiagnosisOlink Holding AB (publ) reported the publication of a landmark study using the Olink Explore platform to identify proteins in the blood that may provide a 7-year warning for various cancers. The findings, published in Nature Communications, illustrate the tremendous potential of proteomics to revolutionize cancer detection, allowing for intervention at much earlier stages, potentially leading to better treatment outcomes and even prevention. Early Detection - A Game Changer. In the groundbreaking work, conducted by Oxford Population Health and funded by Cancer Research UK, researchers describe how they used Olink's next-generation proteomics platform to analyze blood samples from over 44,000 individuals. They were able to pinpoint 371 proteins linked to 19 different cancers, including 107 proteins that were detectable in individuals more than seven years before cancer diagnosis. Olink - Unlocking the Power of Proteomics. Olink's innovative proteomics solution played a pivotal role in the Oxford Population Health research. Owing to its scalability and specificity, researchers were able to accurately analyze a huge number of proteins across tens of thousands of samples, uncovering crucial information hidden within the human body's complex protein makeup. This study is a powerful example of how proteomics is driving a new era of discovery. Details of the study will be presented as part of the Olink Proteomics Corporate Symposium at European Society of Human Genetics conference in Berlin on June 1 - 4. Dr Atkins, alongside other speakers, will describe how the UK Biobank Pharma Proteomics Project, the world's largest proteomics study backed by 13 leading pharmaceutical companies, analyzed samples from over 54,000 participants and identified over 20,000 novel genetic associations with plasma protein levels, finally helping to bridge the gap between genetics and disease pathology. The Road ahead - Refining and Developing Solutions. While these findings hold immense promise for the future of cancer management, the research team emphasized the need for further investigation. Understanding the specific role these proteins play in cancer development and identifying the most reliable ones for testing are crucial next steps.
Reported Earnings • May 13First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.11 loss in 1Q 2023)First quarter 2024 results: US$0.13 loss per share (further deteriorated from US$0.11 loss in 1Q 2023). Revenue: US$28.8m (up 4.7% from 1Q 2023). Net loss: US$16.1m (loss widened 15% from 1Q 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Mar 26Forecast breakeven date pushed back to 2025The 4 analysts covering Olink Holding previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of US$12.4m in 2025. Average annual earnings growth of 61% is required to achieve expected profit on schedule.
お知らせ • Jul 11Olink Holding AB (publ)(NasdaqGM:OLK) dropped from NASDAQ Composite IndexOlink Holding AB (publ) has been dropped from NASDAQ Composite Index .
Breakeven Date Change • Jul 11Forecast breakeven date moved forward to 2024The 4 analysts covering Olink Holding previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of US$11.3m in 2024. Earnings growth of 152% is required to achieve expected profit on schedule.
お知らせ • Jun 08Olink® Target 48 Immune Surveillance Panel – the Next Frontier in Immune Biomarker Profiling with Absolute ConfidenceOlink Holding AB (publ) announced the introduction of Olink Target 48 Immune Surveillance, a validated multiplexed protein assay panel that offers a detailed view of the immune system for in-depth monitoring of inflammation and immune response in clinical research. Biomarker selection for Olink Target 48 Immune Surveillance were designed to give researchers the most effective platform for detecting and quantifying up to 44 well-established biomarkers across key immunological processes in as little as 1µL of sample. When combined with the Olink Target 48 Cytokine panel, scientists can simultaneously detect and quantify up to 89 immune-related proteins while still only using 2µL of sample. This represents a powerful new tool for identifying protein signatures across a range of important therapeutic areas including inflammation, immune response, immuno-oncology and infectious diseases. Developed using Olink’s proven PEA™ technology, Olink Target 48 Immune Surveillance delivers complete confidence with transparent quality control. In addition to internal quality control and validation, Olink works closely with the research community to further test, validate, and improve the performance of products.
お知らせ • May 31Researchers Use Olink®? Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before DiagnosisOlink Holding AB (publ) reported the publication of a landmark study using the Olink Explore platform to identify proteins in the blood that may provide a 7-year warning for various cancers. The findings, published in Nature Communications, illustrate the tremendous potential of proteomics to revolutionize cancer detection, allowing for intervention at much earlier stages, potentially leading to better treatment outcomes and even prevention. Early Detection - A Game Changer. In the groundbreaking work, conducted by Oxford Population Health and funded by Cancer Research UK, researchers describe how they used Olink's next-generation proteomics platform to analyze blood samples from over 44,000 individuals. They were able to pinpoint 371 proteins linked to 19 different cancers, including 107 proteins that were detectable in individuals more than seven years before cancer diagnosis. Olink - Unlocking the Power of Proteomics. Olink's innovative proteomics solution played a pivotal role in the Oxford Population Health research. Owing to its scalability and specificity, researchers were able to accurately analyze a huge number of proteins across tens of thousands of samples, uncovering crucial information hidden within the human body's complex protein makeup. This study is a powerful example of how proteomics is driving a new era of discovery. Details of the study will be presented as part of the Olink Proteomics Corporate Symposium at European Society of Human Genetics conference in Berlin on June 1 - 4. Dr Atkins, alongside other speakers, will describe how the UK Biobank Pharma Proteomics Project, the world's largest proteomics study backed by 13 leading pharmaceutical companies, analyzed samples from over 54,000 participants and identified over 20,000 novel genetic associations with plasma protein levels, finally helping to bridge the gap between genetics and disease pathology. The Road ahead - Refining and Developing Solutions. While these findings hold immense promise for the future of cancer management, the research team emphasized the need for further investigation. Understanding the specific role these proteins play in cancer development and identifying the most reliable ones for testing are crucial next steps.
Reported Earnings • May 13First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.11 loss in 1Q 2023)First quarter 2024 results: US$0.13 loss per share (further deteriorated from US$0.11 loss in 1Q 2023). Revenue: US$28.8m (up 4.7% from 1Q 2023). Net loss: US$16.1m (loss widened 15% from 1Q 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Mar 26Forecast breakeven date pushed back to 2025The 4 analysts covering Olink Holding previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of US$12.4m in 2025. Average annual earnings growth of 61% is required to achieve expected profit on schedule.
Reported Earnings • Mar 26Full year 2023 earnings released: US$0.25 loss per share (vs US$0.11 loss in FY 2022)Full year 2023 results: US$0.25 loss per share (further deteriorated from US$0.11 loss in FY 2022). Revenue: US$169.6m (up 21% from FY 2022). Net loss: US$31.6m (loss widened 146% from FY 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
お知らせ • Mar 09Olink Holding AB (publ), Annual General Meeting, Apr 19, 2024Olink Holding AB (publ), Annual General Meeting, Apr 19, 2024.
お知らせ • Jan 18Olink Holding AB Announces Promotion of Maria Liminga Björk to Chief Research and Development OfficerOn January 16, 2024, Olink Holding AB announced the promotion of Maria Liminga Björk (PhD) to Chief Research and Development Officer. Ms. Björk joined Olink as Vice President of Research and Development in March 2023. Prior to her role at Olink, Ms. Björk served as Director of BioProcess Research and Development at Cytiva, a Danaher Corporation subsidiary, from 2020 to 2023. In this role, Ms. Björk led an organization responsible for development of novel purification solutions for the biopharmaceutical industry. From 2016 to 2020, Ms. Björk directed the Resin and Ligand Department at GE HealthCare Technologies Inc. (d/b/a GE HealthCare). Ms. Björk holds a Masters in Pharmaceutical Biosciences and a PhD in Biochemical Pharmacology from Uppsala University.
Reported Earnings • Nov 17Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0.011 loss in 3Q 2022)Third quarter 2023 results: US$0.01 loss per share. Revenue: US$44.2m (up 39% from 3Q 2022). Net loss: US$1.82m (loss widened 41% from 3Q 2022). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
お知らせ • Oct 26Olink Holding AB (publ) to Report Q3, 2023 Results on Nov 15, 2023Olink Holding AB (publ) announced that they will report Q3, 2023 results Pre-Market on Nov 15, 2023
お知らせ • Oct 07Olink Holding AB (publ) Demonstrates the Power of the Olink Explore Platform for Driving Impactful Proteogenomic Studies At the Population ScaleOlink Holding AB (publ) reported the publication of three articles in the prestigious scientific journal, Nature, that demonstrate the power of the Olink Explore platform for driving impactful proteogenomic studies at the population scale. The studies each used data generated from the UK Biobank Pharma Proteomics Project (UKB-PPP), whereby 13 pharmaceutical companies generated new proteomic data from accessing the UK Biobank. Using the Olink Explore platform, researchers measured around 3,000 proteins in more than 54,000 UKB participant samples. By combining genomic and proteomic analyses at an unprecedented scale, a wealth of new information is available on the genetic effects on protein expression and phenotypic outcomes. The findings illustrate the immense value of proteogenomics in elucidating biological mechanisms, identifying actionable new biomarkers, and accelerating drug development efforts. The paper by Sun et al. from the UKB-PPP consortium provides the first detailed summary of the data, accompanied by downstream GWAS-based proteogenomic analyses, protein quantitative trait loci (pQTL) mapping, cross- section disease associations, and proteomic predictions of demographic factors and physiological functions. By uncovering over 14,000 genetic associations with protein expression levels, 81% of which are novel, their findings from this landmark paper clearly show the importance of high-throughput protein measurements for identifying important biological pathways and their impact on health. A second paper by Dhindsa et al., primarily authored by consortium members from AstraZeneca, used the dataset described in the paper to study genetic associations of rare protein-coding variants with protein expression. The results shed light on the vital role of rare variants in plasma protein level variation and biological outcomes, further underscoring the crucial need for large-scale proteogenomic studies to enable such discoveries. The third article by Eldjarn et al. describes a study where the Olink-generated results in the UKB-PPP dataset were compared to the proteogenomic analysis of a large Icelandic population cohort using an aptamer-based technology. While both platforms identified a large number of genetic associations with protein levels, a significantly higher proportion of the proteins measured using Olink (72% versus 43% when using the aptamer-based technology) had cis-pQTLs associated with them, providing strong genetic corroboration for superior specificity of the Olink assays. Furthermore, median CV ratios were lower for the Olink assays, indicating they were more precise on average.
お知らせ • Sep 19Olink Holding AB (Publ) Announces the Introduction of Olink(R) Target 48 Mouse Cytokine PanelOlink Holding AB (publ) announced the introduction of Olink(R) Target 48 Mouse Cytokine Panel, a validated multiplexed protein panel that offers a detailed view of the murine immune system, enabling in-depth disease modelling, longitudinal studies and translational research. The Olink Target 48 Mouse Cytokine Panel represents a new standard in immunoassays giving researchers the ability to accurately measure 43 carefully selected immune-related proteins using as little as 1ul of sample volume. Offering multiplexing with unparalleled specificity combined with high sensitivity, the T48 Mouse Cytokine panel unlocks true longitudinal studies over multiple timepoints in individual mice. The transparent validation and streamlined workflow maintains the exceptional standards of performance that users have come to expect from Olink. The addition of a targeted mouse panel with absolute quantification capabilities adds to Olink`s broad portfolio of proteomics solutions. From pre-clinical mouse models to human clinical applications, Olink provides solutions encompassing all stages of drug development and disease modelling. The Olink Target 48 Mouse Cytokine Panel was designed to deliver an in-depth view of cytokine signalling and inflammatory pathways for pre-clinical and translational research. It can be utilized across key application areas to deepen current understanding of molecular pathways involved in the disease initiation and progression. Olink Target 48 Mouse Cytokine Panel is fully compatible with the Olink(R) Signature Q100, a high performance, auto-calibrated instrument for data readout that facilitates unattended operation. Work efficiency is further increased by the streamlined assay workflow with minimal hands-on time.
Breakeven Date Change • Aug 11Forecast breakeven date moved forward to 2024The 5 analysts covering Olink Holding previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of US$15.8m in 2024. Average annual earnings growth of 60% is required to achieve expected profit on schedule.
お知らせ • Aug 10Olink Holding AB (Publ) Reiterates Revenue Guidance for the Full Year 2023Olink Holding AB (publ) reiterated revenue guidance for the full year 2023. For the year, company expects revenue guidance of $192 million to $200 million.
Reported Earnings • Aug 10Second quarter 2023 earnings released: US$0.067 loss per share (vs US$0.04 loss in 2Q 2022)Second quarter 2023 results: US$0.067 loss per share (further deteriorated from US$0.04 loss in 2Q 2022). Revenue: US$29.4m (up 7.0% from 2Q 2022). Net loss: US$8.27m (loss widened 72% from 2Q 2022). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
お知らせ • Jul 14Olink Holding AB (publ) to Report Q2, 2023 Results on Aug 09, 2023Olink Holding AB (publ) announced that they will report Q2, 2023 results Pre-Market on Aug 09, 2023
お知らせ • Jul 13Olink Holding AB (Publ) Announces the Introduction of Olink(R) Explore HtOlink Holding AB (publ) announced the introduction of Olink(R) Explore HT, a transformational solution for high-throughput proteomics delivering unmatched specificity, scalability, and workflow simplicity. Olink Explore HT represents a significant advancement in next generation proteomics, allowing scientists to accurately measure over 5,300 proteins using only 2ul of sample with a completely reimagined and streamlined workflow, including a highly automated data analysis platform. In addition to delivering over 80% more unique protein assays than the previous generation product, Olink Explore HT increases sample throughput by 4X and data output by 7X with a >30% reduction in cost per data point and >20% reduction in workflow processing cost. Importantly, these innovations substantially reduce the environmental footprint with a 6-fold decrease in components and 10-fold reduction in boxes. Olink Explore HT was designed to unlock the immense value of proteomics at any scale and advance multi-omic research. It can be utilized across a wide range of therapeutic areas to deepen current understanding of molecular pathways involved in the development, progression, and outcome of disease. Olink Explore HT will also empower new discoveries in drug development, from target discovery based on identification of proteins causal in disease, to actionable insights into mode of action studies and repurposing of therapeutics from reinterrogation of existing samples from clinical trials.
Buying Opportunity • May 14Now 21% undervaluedOver the last 90 days, the stock is up 1.0%. The fair value is estimated to be €25.47, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 39% over the last year. Earnings per share has grown by 64%. Revenue is forecast to grow by 48% in a year. Earnings is forecast to grow by 35% in the next year.
Reported Earnings • May 12First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.10 loss in 1Q 2022)First quarter 2023 results: US$0.11 loss per share (further deteriorated from US$0.10 loss in 1Q 2022). Revenue: US$27.5m (up 21% from 1Q 2022). Net loss: US$14.0m (loss widened 15% from 1Q 2022). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
お知らせ • May 12Olink Holding AB (Publ) Provides Earnings Guidance for the Year 2023Olink Holding AB (publ) provided earnings guidance for the year 2023. For the year, the company expects full year reported revenue to be in the range of $192 million to $200 million, representing growth of approximately 37% to 43% on a reported basis, and growth of approximately 38% to 44% on a constant currency basis.
Buying Opportunity • Mar 28Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be €26.15, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 38% over the last 3 years. Earnings per share has grown by 116%. Revenue is forecast to grow by 41% in a year. Earnings is forecast to decline by 26% in the next year.
Breakeven Date Change • Feb 22Forecast to breakeven in 2024The 6 analysts covering Olink Holding expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$8.56m in 2024. Average annual earnings growth of 84% is required to achieve expected profit on schedule.
Reported Earnings • Feb 22Full year 2022 earnings released: US$0.11 loss per share (vs US$0.43 loss in FY 2021)Full year 2022 results: US$0.11 loss per share (improved from US$0.43 loss in FY 2021). Revenue: US$139.8m (up 47% from FY 2021). Net loss: US$12.9m (loss narrowed 70% from FY 2021). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
Buying Opportunity • Jan 21Now 20% undervaluedOver the last 90 days, the stock is up 12%. The fair value is estimated to be €22.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 38% over the last 3 years. Earnings per share has grown by 116%. Revenue is forecast to grow by 45% in a year. Earnings is forecast to grow by 32% in the next year.
お知らせ • Jan 10+ 1 more updateOlink Holding AB (publ) to Report Fiscal Year 2022 Results on Feb 21, 2023Olink Holding AB (publ) announced that they will report fiscal year 2022 results Pre-Market on Feb 21, 2023
Buying Opportunity • Jan 05Now 22% undervaluedOver the last 90 days, the stock is up 49%. The fair value is estimated to be €26.20, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 38% over the last 3 years. Earnings per share has grown by 116%. Revenue is forecast to grow by 46% in a year. Earnings is forecast to grow by 43% in the next year.
Reported Earnings • Nov 16Third quarter 2022 earnings released: US$0.011 loss per share (vs US$0.046 loss in 3Q 2021)Third quarter 2022 results: US$0.011 loss per share (improved from US$0.046 loss in 3Q 2021). Revenue: US$31.8m (up 59% from 3Q 2021). Net loss: US$1.29m (loss narrowed 77% from 3Q 2021). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
Board Change • Nov 16High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 2 experienced directors. No highly experienced directors. Director Tommi Unkuri is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Nov 15Olink® Flex, A New, Unique and Fully Flexible Low-Plex Proteomics Solution Using Absolute QuantificationOlink Holding AB (publ) announced that it is now taking orders for Olink® Flex, a fully flexible made-to-order product to select and combine up to 21 human proteins using absolute quantification in one biomarker panel. With the introduction of Olink® Flex, the Company offers a mix-and-match solution for efficient creation of custom protein biomarker panels with uncompromised data quality, unparalleled specificity, high sensitivity, broad dynamic range, and short turnaround time. Additionally, the solution features absolute quantification methodology for protein concentration measurement, an important feature for many applications spanning clinical to basic research. Using an online panel builder in Olink® Insight, customers can freely pick and choose 15 to 21 pre-validated assays from over 200 human protein biomarkers covering major biological pathways such as inflammation, immuno-oncology and oncology, neurology, and cardiovascular disease. With this new product line, Olink enables customers to easily design customized biomarker panels that include the protein assays of their choice, tailored to specific research needs. This latest high-performance solution based on Olink® Proximity Extension Assay (PEA) technology accelerates targeted protein biomarker studies in academic and clinical research to investigate inflammatory processes and immune responses, understand mechanisms of disease and validate unique biomarker signatures. Olink Flex is fully compatible with Olink® Signature Q100, a low maintenance, auto-calibrated instrument for data readout that facilitates unattended operation. Work efficiency is further increased by the streamlined assay workflow with minimal hands-on time and no need for time-consuming washing steps. With this latest addition, the Olink technology platform now scales from the high-plex product Olink® Explore 3072, to mid-plex Olink® Target 96 and Target 48, down to customized low-plex Olink® Focus and Olink® Flex.
Reported Earnings • Nov 11Third quarter 2022 earnings released: US$0.01 loss per share (vs US$0.046 loss in 3Q 2021)Third quarter 2022 results: US$0.01 loss per share (improved from US$0.046 loss in 3Q 2021). Revenue: US$31.8m (up 59% from 3Q 2021). Net loss: US$1.29m (loss narrowed 77% from 3Q 2021). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
お知らせ • Nov 11+ 1 more updateOlink Holding AB (publ) Provides Earnings Guidance for the Full Year 2022Olink Holding AB (publ) provides earnings guidance for the full year 2022. For the period, the company expects revenue to be in the range of $138 million and $142 million.
お知らせ • Oct 25Olink Holding AB (Publ) Announces the Launch of Olink(R) InsightOlink Holding AB (publ) announced the launch of Olink(R) Insight, providing customers with an open-access online platform to share knowledge, with multiple tools to simplify users' data experiences, and to provide more timely insights from their protein studies. Olink(R) Insight has been created from the ground up to address the complex challenges of proteomic data analysis, introducing a modern and user-friendly new interface to explore Olink(R) NPX(TM) data, which will help to deliver on the urgent scientific questions asked by the community. With this new digital platform, Olink makes a long-term commitment to develop and implement features for customers that simplify the data management experience and leverage its considerable value. The user data journey is improved with tools that help translate biological pathways to generate a list of candidate protein biomarkers, enabling improved experiment planning and setup, post-run data analysis; and with analytical tools, applications, scripts, and shared expertise, to provide users a faster time to value with their data. Olink(R) Insight Product details and functionalities An open-access online portal that supports users in understanding and interpreting their proteomics data, by visualizing initial findings and thereby achieving insights faster. Its significant features include: PathwaE Explorer - Graphically represents the proteome and coverage of Olink panels in biological pathways. Explplores which proteins are involved in a specific pathway to help with interpretation of data and generation of actionable results. Reveals and helps users understand connections between proteins and human biology. Built on Reactome, an open-source peer reviewed database. Annotation - Draw biological conclusions from proteomic data by listing biomarker-specific information about tissue specificity, how the corresponding gene functions at the molecular level, where in the cell it functions, what biological processes it helps to carry out, and variability in a normal cohort. Normal Ranges - Explore the natural variability of proteins before selecting biomarkers for a study; or after analysis, compare outcomes to observed variability in samples to that of a "normal" cohort. A reference database based on protein profiling of healthy individuals. Disease Atlas (by year end) - Compare and explore observed protein expression profiles in the most common diseases, generated by protein profiling of patients. The first version of the Disease Atlas will focus on cancer, and will later expand to include other common diseases, such as cardiovascular, neurological, infectious, and autoimmune diseases; as well as other conditions. Publication Explorer - Get fast insights into proteins of interest, such as a list of significant hits from a study; based on cutting-edge abstract mining technology. Find key abstracts where significant hits co-occur with each other, with key words, and diseases. Data Stories - Showcase Olink 'best practice analytics' on a real and relevant publicly available data set demonstrating how results can be analyzed and visualized in practice.
お知らせ • Oct 14Olink Holding AB (publ) to Report Q3, 2022 Results on Nov 10, 2022Olink Holding AB (publ) announced that they will report Q3, 2022 results Pre-Market on Nov 10, 2022
お知らせ • Sep 01Olink Holding AB (Publ) Announces Management AppointmentsOlink Holding AB (publ) announced several appointments in its leadership structure. Olink Chief Commercial Officer (CCO) Carl Raimond will be appointed President, effective upon the hiring of a new CCO, which is expected by the end of the year. In the interim, Carl will continue his strong stewardship of the commercial organization during Olink’s second half of 2022 and lead the transition of CCO duties. In this newly created position, Carl’s role will expand from leadership of the commercial group to responsibility for corporate functions, while continuing to report to CEO Jon Heimer. In addition, Anna Marsell will become Chief Operating Officer (COO) effective December 1st, 2022. Anna has a strong track record in transforming and scaling growth-driven international organizations and will join Olink from Galderma where she has held several leadership positions with increasing responsibility over the past ten years, including General Manager/Head of Nordic, and senior roles in decision support and strategic planning. Olink’s current COO, Fredrik Netzel, will be appointed VP Operations, his role to include management of Olink’s supply chain, a function of critical importance to Olink’s success and differentiation. Carl Raimond has served as Olink’s CCO since October 2020, previously serving as the Company’s Senior Vice President of Sales beginning in August 2020. Prior to Olink, he served in various executive commercial leadership roles at PerkinElmer Inc. including Vice President and General Manager of Americas Sales and Service, as well as Global Vice President and General Manager of Sales and Service for the Discovery and Analytical Solutions Division. Before this, he served as the Vice President and General Manager of the Americas Life Science Sales & Field Operations of Agilent Technologies Inc. Carl received his Bachelor of Arts in zoology from State University of New York College at Oswego, and his Master of Science in biology from State University of New York College at Brockport. Anna Marsell brings more than 15 years of international experience from the pharma and medtech industry with various roles in R&D, project management, sales and marketing, as well as company governance and general management. Her most recent role is General Manager for the Nordic region of Galderma, delivering sustainable organic growth and increased market share. During her 10 years at Galderma she has held various senior leadership roles in global strategic marketing, product development, commercial operations, Uppsala Site management, as well as in strategic corporate governance when based in Galderma HQ in Lausanne, Switzerland. Prior to joining Galderma, Anna spent 7 years in various R&D and product marketing roles within medtech, focused on cardiovascular technology at Radi Medical Systems and St. Jude Medical in the U.S. and Sweden. Anna is an inspirational leader with a strong track record in delivering outstanding commercial results, driving innovation and in managing high-performing teams. She holds a Master’s in Molecular Biotechnology from Uppsala University and an Associate’s Certificate in Project Management from The George Washington University and ESI International.
Reported Earnings • Aug 12Second quarter 2022 earnings released: US$0.04 loss per share (vs US$0.089 loss in 2Q 2021)Second quarter 2022 results: US$0.04 loss per share (up from US$0.089 loss in 2Q 2021). Revenue: US$27.5m (up 56% from 2Q 2021). Net loss: US$4.82m (loss narrowed 55% from 2Q 2021). Over the next year, revenue is forecast to grow 52%, compared to a 13% growth forecast for the industry in Germany.
お知らせ • Aug 12Olink Holding AB (Publ) Provides Revenue Guidance for the Fiscal Year 2022Olink Holding AB (publ) provided revenue guidance for the fiscal year 2022. for the year, the company expects revenue in range of $138 million to $145 million and continues to expect revenue will be weighted toward the second half of the year and fourth quarter specifically.
お知らせ • Jul 15Olink Holding AB (publ) to Report Q2, 2022 Results on Aug 11, 2022Olink Holding AB (publ) announced that they will report Q2, 2022 results Pre-Market on Aug 11, 2022
お知らせ • Jun 29Release of Olink Analyze 3.1 Streamlines Proteomic Analysis to Connect Data to Biological InsightOlink Holding AB (publ) announced the release of Olink® Analyze 3.1. Olink® Analyze is an R software package, a collection of functions written in R programming language, created to streamline the analysis of Olink data. R is a free and open-source programming language that is widely used for statistics and data science. Olink® Analyze enables users to easily extract biological insight from Olink data using built-in statistical analysis and visualization functions and expedites the data analysis process with quality control visualizations and easy integration with other R packages. Regardless of what Olink product is being used, Olink® Analyze 3.1 can help expedite the analysis pipeline. For the Olink® Target 48 product for analysis of immune response proteins, non-parametric functions have been added to easily analyze data in absolute quantification. For hypothesis generating studies, like those run with Olink® Explore 3072 for simultaneous analysis of up to 3,000 proteins, the heatmap function makes it even easier to detect global trends in Olink data. Pathway enrichment functions enable a seamless connection between statistical results and biological meaning. Olink® Analyze functions also help with data pre-processing, quality control and exploratory data analysis, statistical analysis, and data visualization. Olink® Analyze is easily accessible and can be installed from the Comprehensive R Archive Network (CRAN), R’s central software repository, and has undergone manual and automated review by CRAN maintainers. Whether trying to get a sense of data, developing new hypotheses, or looking for biomarkers of interest, Olink® Analyze can streamline the analysis process to get from data to insight faster.
Reported Earnings • May 13First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.48 loss in 1Q 2021)First quarter 2022 results: US$0.10 loss per share (up from US$0.48 loss in 1Q 2021). Revenue: US$22.7m (up 66% from 1Q 2021). Net loss: US$12.2m (loss narrowed 34% from 1Q 2021). Over the next year, revenue is forecast to grow 51%, compared to a 13% growth forecast for the industry in Germany.
お知らせ • May 13Olink Holding AB (publ) Provides Revenue Guidance for the Year 2022Olink Holding AB (publ) provided revenue guidance for the year 2022. Revenue guidance range of $138 million to $145 million and continues to expect revenue will be weighted toward the second half of the year and fourth quarter specifically.
Breakeven Date Change • May 08Forecast breakeven date moved forward to 2023The 3 analysts covering Olink Holding previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 47% to 2022. The company is expected to make a profit of US$2.50m in 2023. Average annual earnings growth of 98% is required to achieve expected profit on schedule.
Board Change • Apr 27High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 2 experienced directors. No highly experienced directors. Director Tommi Unkuri is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 22Olink Holding AB (publ) to Report Q1, 2022 Results on May 12, 2022Olink Holding AB (publ) announced that they will report Q1, 2022 results Pre-Market on May 12, 2022
Breakeven Date Change • Apr 13Forecast to breakeven in 2024The 4 analysts covering Olink Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 68% per year to 2023. The company is expected to make a profit of US$21.7m in 2024. Average annual earnings growth of 91% is required to achieve expected profit on schedule.
お知らせ • Apr 08Olink Holding AB (publ) Announces Board AppointmentsOlink Holding AB (publ) at its AGM held on April 7, 2022, approved the appointment of Robert Schueren and Mary Reumuth as new Board Members.
お知らせ • Feb 15Olink Holding AB (publ) Provides Revenue Guidance for 2022Olink Holding AB (publ) provided revenue guidance for 2022. The company expects full year 2022 revenue will be in the range of $138 million to $145 million, progressing along a seasonal pattern similar to 2021.
Reported Earnings • Feb 15Full year 2021 earnings: Revenues exceed analyst expectationsFull year 2021 results: Revenue: US$95.0m (up 76% from FY 2020). Net loss: US$38.3m (loss widened 79% from FY 2020). Revenue exceeded analyst estimates by 2.5%. Over the next year, revenue is forecast to grow 50%, compared to a 27% growth forecast for the pharmaceuticals industry in Germany.
お知らせ • Jan 12Olink Holding AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2022Olink Holding AB (publ) provided earnings guidance for the fourth quarter and full year 2022. For the quarter, the company's Revenues is expected to be between $43.2 million and $43.7 million, versus $27.2 million in the corresponding quarter of last year.For the year, the company's Revenues is expected to be between $94.5 million and $95.0 million, an increase of approximately 75% compared to the year ended December 31, 2020.
Board Change • Dec 31High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Director Tommi Unkuri is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Dec 02Olink Holding AB (Publ) Announces Delivery of Olink® Explore 3072 Is Now StartingOlink Holding AB (publ) announced that the delivery of Olink® Explore 3072 is now starting, providing customers with access to its expanded library of approximately 3,000 carefully curated and validated assays that together cover of all major biological pathways. With the introduction of Olink® Explore 3072, the company offers customers the possibility to run either 96 or 384 samples per run. This means that the throughput will increase significantly, and customers can process over 4,600 samples per week per system, with almost 3,000 proteins measured for each sample. Moving from Olink® Explore 1536 to Olink® Explore 3072 increases the overall dynamic range covered by the Olink library. This will enable measurement of proteins present in higher concentration in the sample than was possible in earlier versions of the platform, such as the PSA protein, which is a key biomarker for prostate cancer diagnosis. Olink® Explore 3072 significantly increases the sample and assay throughput, and in addition expands the company's protein biomarker discovery offering, featuring its proprietary Proximity Extension Assay (PEA) high-multiplex immunoassay technology combined with next-generation sequencing (NGS) readout on the Illumina® NovaSeq and Illumina® NextSeq platforms. With this expansion, Olink will 1) double the number of available protein biomarkers, covering all major biological pathways, 2) increase the throughput, and 3) increase the dynamic range, especially for higher abundant proteins, while maintaining unparalleled sensitivity, specificity, and precision.
お知らせ • Nov 24Olink Holding AB (publ) Announces Delivery of Olink® Signature Q100Olink Holding AB (publ) announced that it is now starting the delivery of Olink® Signature Q100, facilitating hands-on access for researchers to Olink technology with a new benchtop system dedicated to multiplex protein biomarker measurement. Olink® Signature Q100 now offers a new solution designed for readout of Olink® Target and Olink® Focus protein biomarker panels, enabling researchers to run Olink kits more easily and conveniently in their own labs using as little as one microliter of plasma or serum to measure protein concentrations for up to 92 proteins simultaneously. This new instrument will allow more researchers to access high-quality proteomics data with Olink technology. Key features: Developed specifically for the high quality of Olink® Target 96/48 and Focus (custom designed) protein biomarker panels, as well as future custom biomarker solutions presently under development – currently covering over 1100 different thoroughly validated protein assays. Low investment threshold, broadening access to protein biomarker analysis to more researchers than ever before. User-focused design and intuitive interface, including integrated software and IFC loader. Small, compact footprint.
Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.046 loss per shareThe company reported a soft third quarter result with weaker control over costs, although losses were stable and revenues were flat. Third quarter 2021 results: Revenue: US$20.0m (flat on 3Q 2020). Net loss: US$5.47m (flat on 3Q 2020).
お知らせ • Aug 12Olink Holding AB (Publ) Provides Earnings Guidance for the Year 2021Olink Holding AB (publ) provided earnings guidance for the year 2021. The company expects revenue to be in the range of $90 million to $92 million.
お知らせ • Jul 23Olink Holding AB (publ) Announces UK Biobank Pharma Proteomics Project's Expansion of Ongoing Proteomics Study Of 53,000 Participants to the New Olink Explore 3072 PlatformOlink Holding AB (publ) announced that the UK Biobank Pharma Proteomics Project (UKB-PPP Consortium) has decided to expand the ongoing proteomics study of 53,000 participants to the new Olink® Explore 3072 platform, providing access to Olink´s expanded library of approximately 3,000 carefully curated and validated assays. The UK Biobank Pharma Proteomics Project (UKB-PPP), a partnership between UK Biobank and biopharmaceutical companies, is currently performing a large scientific studies of blood protein biomarkers conducted to date of 53,000 UK Biobank participants. The study aims to enable better understanding of disease biology and support innovative drug development for more effective therapies. Initially funded by ten biopharmaceutical companies, the consortium has now grown to twelve companies, further emphasizing the value of this important work. By expanding the study from Olink Explore 1536 to the new Olink Explore 3072 platform, utilizing Next Generation Sequencing (NGS) as a read-out to measure plasma protein concentration, UKB-PPP will double the number of available assays from almost 1,500 to close to 3,000. UK Biobank is a large-scale, biomedical database and research resource containing in-depth genetic and health information from half a million UK participants. The database, which is regularly augmented with additional data, is globally accessible to approved researchers and scientists undertaking vital research into the most common and life-threatening diseases. The project includes analysis of 56,000 samples from 53,000 participants and is funded by the twelve participating companies in UKB-PPP.
お知らせ • Jul 16Olink Holding AB (publ) has completed a Follow-on Equity Offering in the amount of $232.5 million.Olink Holding AB (publ) has completed a Follow-on Equity Offering in the amount of $232.5 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Securities Offered: 7,500,000 Price\Range: $31
お知らせ • Jul 14Olink Holding AB (publ) Provides Preliminary Unaudited Earnings Guidance for the Second Quarter Ended June 30, 2021Olink Holding AB (publ) provided preliminary unaudited earnings guidance for the second quarter ended June 30, 2021. For the period, the company expects revenue to be between $17.3 million and $17.7 million, compared to $7.9 million for the corresponding quarter of last year. Net loss to be between $10.4 million and $10.8 million, compared to $2.0 million for the corresponding quarter of last year.
お知らせ • Jun 24Olink Announces the New Explore 3072 High Throughput Proteomics PlatformOlink Holding AB announced that it is taking orders for Olink Explore 3072, providing customers with access to its expanded library of 3,000 carefully curated and validated assays. Olink® Explore 3072 significantly expands the company's Explore protein biomarker discovery offering, featuring its proprietary Proximity Extension Assay (PEA) high-multiplex immunoassay technology combined with next-generation sequencing (NGS) readout on the Illumina® NovaSeq and Illumina® NextSeq platforms. With this expansion, Olink will double the number of available protein biomarker targets, covering all major biological pathways, and increasing the dynamic range while maintaining unparalleled sensitivity, specificity and precision. By using Olink Explore 3072, customers can experience a throughput of just over 4,600 samples per week per system, with almost 3000 proteins measured for each sample. The company will begin taking orders for kits and studies based on the expanded library beginning June 23, 2021, with deliveries expected to begin in the fourth quarter, 2021. Product details: Olink Explore 3072 enables rapid measurement of almost 3,000 human proteins in only 6 µL of plasma or serum. These carefully selected proteins provide broad coverage of the low abundant plasma proteome as well as broadening the dynamic range of the library to include more high-abundant proteins, and represent the latest step in the development of Olink's planned NGS-based library. The power of the NGS platform combined with an automation-enabled assay workflow enables unprecedented levels of throughput, with up to 14 million protein measurements/ week/ system. Each thoroughly validated assay maintains the exceptional standards of specificity, sensitivity, precision and dynamic range that Olink users have come to expect.
お知らせ • Jun 16SCALLOP Launches Clinical Trial Arm to Uncover Next Level of Drug Target Insights from Proteomic ProfilingOlink Holding AB (publ) announced that the SCALLOP consortium (Systematic and Combined AnaLysis of Olink Proteins), a collaborative framework for discovery and follow-up of genetic associations with proteins on the Olink Proteomics platform, is launching a new clinical trial arm to bring together actors working on proteomic profiling in clinical trials. The new initiative is designed to enhance insights from clinical trial proteomic profiling, boost statistical power and uncover the next level of drug target insights. The participants will have access to a dedicated project coordinator and a GDPR compliant secure server that can be remotely accessed. The SCALLOP clinical trial arm initiative offers a uniform price of Olink protein profiling.
お知らせ • May 21Olink Holding AB (Publ) Provides Earnings Guidance for the Year 2021Olink Holding AB (publ) provided earnings guidance for the year 2021. The company expected full year 2021 revenue to be in the range of $90 million to $92 million.
お知らせ • May 05Olink Announces First Core Lab Running the Olink Explore Platform in Europe, Making It Available for More ResearchersOlink Holding AB (publ) announced that its Olink® Explore 1536/384 platform is now available to researchers in Europe through the SciLifeLab National Genomics Infrastructure and the Affinity Proteomics Uppsala unit at SciLifeLab Clinical and Immunological platform by their combined capability SciLifeLab Explore lab. This is the first core lab in Europe certified to offer the Olink Explore platform, comprising four protein biomarker panels for cardiovascular and metabolic diseases, oncology, neurology and inflammation. The platform enables researchers to define protein signatures that provide meaningful insights into human biology and dynamic changes in health and disease. Through the launch of Olink® Explore 1536 as kits earlier this year, laboratories are now able to set up the Olink Explore platform, providing additional analysis capacity to researchers. By combining Olink’s patented proximity extension assay technology with a high-throughput next generation sequencing readout on Illumina® NovaSeq and NextSeq instruments, close to 1,500 protein biomarker targets can be measured simultaneously in only a few microliters of biological sample, providing clinically relevant, actionable insights. This year, Olink plans to increase the library to approximately 3,000 protein biomarker targets. The PEA technology is based on two matching antibodies binding to the target protein. When the complementary DNA tags from the two antibodies come into close proximity, the tags hybridize and are extended making a unique DNA barcode for each analyzed protein. After amplification, digital DNA counting is performed using NGS and the resulting counts represent the concentration of the protein in the sample. This project has been made possible by grants from SciLifeLab and the Swedish Research Council’s Access to Infrastructure and by building a new joint-capability lab between NGI and APU at the Biomedical Centre in Uppsala.
